Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    7477169 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Conditions: Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Ibritumomab Tiuxetan (Zevalin)
2 Recruiting The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Condition: B-Cell Lymphoma Originating in the CNS
Intervention: Drug: Temozolomide
3 Terminated Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: MK2206
4 Not yet recruiting A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell
Interventions: Drug: BeEAM;   Drug: BEAM

Indicates status has not been verified in more than two years